<DOC>
	<DOC>NCT01165021</DOC>
	<brief_summary>The purpose of this trial is to assess how well the combination of pemetrexed with cisplatin can reduce tumor size.</brief_summary>
	<brief_title>A Study of Pemetrexed/Cisplatin as Pre-operative Treatment of Early Stage Nonsquamous Non-Small Cell Lung Cancer</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Pemetrexed</mesh_term>
	<mesh_term>Vitamin B 12</mesh_term>
	<mesh_term>Hydroxocobalamin</mesh_term>
	<mesh_term>Folic Acid</mesh_term>
	<criteria>Nonsquamous NonSmall Cell Lung Cancer that was confirmed by tissue biopsy Stage IIIAN2 disease (T1aN2, T1bN2, T2aN2, T2bN2, and T3N2) Tumor considered potentially resectable Good performance status (score of 0 or 1) according to Eastern Cooperative Oncology Group scale (ECOG) No prior therapy for lung cancer Measurable disease according to version 1.1 of Response Evaluation Criteria in Solid Tumors (RECIST) Criteria Life expectancy of at least 6 months Organs are functioning well (bone marrow reserve, liver, kidney, lung) Signed Informed Consent Women must be surgically sterile, postmenopausal, or compliant with a medically approved contraceptive regimen (for example, intrauterine device, birth control pills, or barrier device) during and for 6 months after last dose of study drug; must have a negative pregnancy test within 7 days before study enrollment; and must not be breastfeeding. Men must be surgically sterile, or compliant with a contraceptive regimen during and for 6 months after last dose of study drug. Be fit for surgery at the time of enrollment Receiving or have received an investigational drug or device within the last 30 days Have previously completed or withdrawn from this study or any other study investigating pemetrexed Serious concomitant systemic disorder Serious cardiac condition, such as myocardial infarction within 6 months, angina, or heart disease Receiving concurrent administration of any other anticancer therapy Have received a recent (within 30 days of enrollment) or are receiving concurrent yellow fever vaccination Inability or unwillingness to take Pemetrexed supplementation/premedication (folic acid, vitamin B12, or corticosteroids) Inability to interrupt aspirin or other nonsteroidal antiinflammatory agents, other than an aspirin dose less than or equal to 1.3 grams per day</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>